We report 6 cases of corticotroph macroadenomas which show heterogeneity of clinical and biological features (from Cushing's syndrome to silent adenoma) and heterogeneity of immunocytochemical staining. One patient reported on had skin hyperpigmentation and ACTH hypersecretion without clear abnormal adrenocortical function; we believe that this patient's plasma contained ACTH with very low bioactivity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0248-8663(05)80107-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical and Surgical Approaches for a Non-functioning Pituitary Adenoma During Pregnancy.
Cureus
March 2024
Gynecology, University Hospital of Farhat Hached, Sousse, TUN.
Non-functioning pituitary adenomas (NFPA) are most commonly found in post-menopausal women and men above the age of 50. They are mainly revealed by a tumor syndrome. The incidence of symptomatic NFPA during pregnancy is rare, with only nine documented cases in the literature.
View Article and Find Full Text PDFDiagnostic and therapeutic difficulties in a patient with corticotropic pituitary macroadenoma.
Endokrynol Pol
July 2023
Deptartment of Endocrinology, Diabetes and Isotope Therapy, Medical University Wroclaw, Wroclaw, Poland.
Not required for Clinical Vignette.
View Article and Find Full Text PDFDelayed identification of massive pituitary apoplexy in pregnancy: A case report.
Int J Surg Case Rep
October 2022
Department of Neurosurgery, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Introduction And Importance: Pituitary apoplexy is a very rare cause of sudden and severe headache with a neuro-ophthalmic deficit during pregnancy due to hemorrhage or infarction in the pituitary gland. Delayed identification can be life-threatening to both mother and baby.
Case Presentation: A 40-year-old nulliparous female without any prior comorbidities in her 21 weeks of gestation presented with complaints of severe headache, vomiting, decreased vision, and altered sensorium for five days.
TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome.
Acta Neuropathol Commun
September 2022
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany.
Corticotroph macroadenomas are rare but difficult to manage intracranial neoplasms. Mutations in the two Cushing's disease mutational hotspots USP8 and USP48 are less frequent in corticotroph macroadenomas and invasive tumors. There is evidence that TP53 mutations are not as rare as previously thought in these tumors.
View Article and Find Full Text PDFCase Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
Front Endocrinol (Lausanne)
August 2022
Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA), Junín, Buenos Aires, Argentina.
Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing's disease. Trustable biomarkers that can predict their aggressive course, as well as their response to traditional or new therapies, are paramount.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!